Table 1. Anatomical measures in hearts of CLN2-affected dogs that received ICV TPP1 gene therapy.

Measurement	Dog 7a 10 months	Dog 6a 10 months	Dog 4 18 months	Dog 1 18 months	Dog 2 21 months	Reference range
H/BW %b	0.78%	0.74%	1.13% ↑	0.93	0.94 ↑	0.58–0.94%
LV+S/RVc	2.86	3.18	2.36 ↓	2.4 ↓	2.42 ↓	2.76–3.88
RV/BW, %d	0.18	0.16	0.27 ↑	0.23 ↑	0.24 ↑	0.1–0.18
LV+S/BW, %e	0.54	0.49	0.65 ↑	0.56 ↑	0.59 ↑	0.35–0.55
RV/TC, %f	23.8 ↑	21.0 ↑	24% ↑	24.9 ↑	25.7 ↑	15.3–20.9%
LV+S/TC, %g	68.2 ↑	66.8 ↑	56	59.7	62.3	52.5–66.5%

^aDogs 6 and 7 were untreated affected dogs; dogs 1, 2 and 4 correspond to the dogs listed in Figures 1, 2, 3.

^bTotal heart weight/body weight.

^cLeft ventricle and septum weight/right ventricle weight.

^dRight ventricle weight/body weight.

^eLeft ventricle and septum weight/body weight.

^fRight ventricle weight/total cardiac weight.

^gLeft ventricle and septum weight/total cardiac weight.